A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum

Study acronym: SEM-BEAT
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to investigate how GLP-1 receptor analogs, such as semaglutide (Wegovy®), influence processes that determine eating behavior, binge eating, and weight regulation via the gut-brain axis. The main question it aims to answer is: to identify for whom semaglutide works best. Participants will: * undergo a semaglutide treatment for 6 months * visit the clinic for 2-4 study checkup and tests * wear a smartwatch and complete questionnaires on their smartphone
Trial Details
NCT Number NCT07870538
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Conditions
(from sponsor)		 Obesity & Overweight
Related terms Obesity, Overweight
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov